NCT06291194 - Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients | Biotech Hunter

Enrollment

396

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Dry Eye Syndromes

Interventions

DRUG

AJU-S56 5%

After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).

DRUG

Placebo Group(Vehicle)

After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).

Trial Locations (1)

Unknown

RECRUITING

AJU Pharm Co., Ltd., Seoul